SCHEMBL14596124

SCHEMBL14596124

CN(C)CCCNc1nc(CN(C)C(=O)Cc2ccc(Cl)cc2Cl)nc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.52
TERT O14746 4/20 0.47
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 1/20 0.46
ERCC1 P07992 1/20 0.46
ERCC4 Q92889 1/20 0.46
RAD52 P43351 4/20 0.44
FLT3 P36888 5/20 0.44
KMT2A Q03164 2/20 0.44
TOP2A P11388 1/20 0.43
SLC2A1 P11166 2/20 0.42
NPC1 O15118 1/20 0.42
APOBEC3A P31941 1/20 0.42
RAB9A P51151 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14596220 0.88 POLB (0.51) POLBTERTALDH1A1MAPK1RAD52
SCHEMBL14596111 0.88 POLB (0.52) POLBTERTALDH1A1MAPK1RAD52
SCHEMBL14596125 0.86 POLB (0.49) POLBTERTALDH1A1MAPK1RAD52
SCHEMBL14596018 0.85 POLB (0.58) POLBTERTALDH1A1MAPK1RAD52
SCHEMBL14596053 0.85 ALDH1A1 (0.55) POLBALDH1A1MAPK1RAD52FLT3
SCHEMBL14596182 0.84 POLB (0.53) POLBTERTALDH1A1MAPK1RAD52
SCHEMBL14596130 0.82 ALDH1A1 (0.49) POLBALDH1A1MAPK1RAD52FLT3
SCHEMBL14596086 0.82 POLB (0.63) POLBTERTALDH1A1MAPK1RAD52
SCHEMBL14596101 0.82 ALDH1A1 (0.56) POLBALDH1A1MAPK1RAD52FLT3
SCHEMBL14596064 0.81 POLB (0.55) POLBTERTALDH1A1MAPK1RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment TP53, TP53BP1, ACIN1 POLB 800/4885TERT 1545/4885ALDH1A1 1994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.